Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (Olmetec®), launched in 2002 by Sankyo and now available in more than 50 countries around the world; the antiplatelet agent prasugrel (Efient®), launched in 2009 for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); and edoxaban (Lixiana®), the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism (VTE).
Daiichi Sankyo is based in Tokyo and today has 50 billion yen in capital.
Daiichi Sankyo Co., Ltd. Head Office
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo